Get the Stockscreener App
1.5672
0.81%
-0.0128
After Hours:
1.57
0.0028
+0.18%
Intercure Ltd stock is traded at $1.5672, with a volume of 9,957.
It is down -0.81% in the last 24 hours and up +3.11% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
See More
Previous Close:
$1.58
Open:
$1.5776
24h Volume:
9,957
Relative Volume:
0.71
Market Cap:
$85.43M
Revenue:
$118.18M
Net Income/Loss:
$5.99M
P/E Ratio:
11.88
EPS:
0.1319
Net Cash Flow:
$-12.91M
1W Performance:
+1.11%
1M Performance:
+3.11%
6M Performance:
+17.83%
1Y Performance:
-46.69%
1-Day Range:
$1.5672
$1.62
1-Week Range:
$1.53
$1.62
52-Week Range:
$1.17
$3.04
Intercure Ltd Stock (INCR) Company Profile
Compare INCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.5672 | 84.49M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
InterCure (NASDAQ:INCR) Shares Down 4.4% – What’s Next? - Defense World
InterCure Reports FY2024 Results - mg Magazine
InterCure Reports Strong Start to 2025 Amid Recovery Efforts - TipRanks
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire
Intercure Ltd. Delays Yearly Report Filing - TipRanks
Interbusiness, Virdis partner to distribute Intercure products - Rubber News
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facility - Globes
InterCure secures $18.2M for post-war recovery By Investing.com - Investing.com Australia
InterCure secures $18.2M for post-war recovery - Investing.com
InterCure Secures Major Funding to Boost Growth - TipRanks
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - Nasdaq
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
InterCure Ltd. (NASDAQ:INCR) Short Interest Update - MarketBeat
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Crain's Chicago Business
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ - Benzinga
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding - GlobeNewswire
Israeli Cannabis Firms Navigate Challenges Amid Hamas Conflict, Cellular Goods Signs New Joint Venture, & More from SEED Innovations - Business of Cannabis -
InterCure Ltd Issues Update Regarding the Security Situation in Israel By Investing.com - Investing.com UK
Israeli Cannabis Adjusts to War - Green Market Report
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY - GlobeNewswire
InterCure Ltd. Announces Proposed Voluntary Delisting from - GlobeNewswire
Cookies launches flagship store in Austria with InterCure - Business of Cannabis
Intercure Counter-Sued By Better, Cantourage Sees Stock Jump 30%, & Tikun Olam Cannbit To Be Acquired - Business of Cannabis
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary - Stock Titan
InterCure to distribute Mike Tyson’s cannabis internationally - Mugglehead Magazine
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries - GlobeNewswire
InterCure Delivers Rising Revenue, Positive Cash Flow - Green Market Report
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results - GlobeNewswire
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
18.36%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):